A steep rise in the number of penny stocks being bought by amateur retail investors might be good news for the companies behind those stocks, but it has some industry watchers worried about the potential for massive fraud.
A Thursday article in The New York Times, citing data from the Financial Industry Regulatory Authority, noted that in February, more than 1.9 trillion transactions were made on over-the-counter markets, an increase of more than 2,000% from the previous year.
OTC markets are a popular place to find penny stocks, which is the designation for more than 10,000 small companies with cheap share prices and questionable business models.
Penny stocks are nothing new — they were particularly popular during the 1920s, when amateur investors flooded the stock markets prior to the 1929 crash. One reason they are booming now is that social media, coupled with boredom during the COVID-19 lockdown, have made it easy for thousands of investors to band together to push up shares of otherwise struggling or worthless companies.
Two of those companies, GameStop and SpectraScience, became sensations earlier this year when amateur investors poured money into them and sent their stock prices soaring.
The danger for investors is that penny stocks exist in a world “rife with fraud and chicanery,” as The New York Times put it, featuring many companies that either don’t have viable products or are swamped in debt. Another danger is that the OTC markets are lightly regulated compared with other markets, with fewer rules governing what companies must disclose in terms of financial performance and independent review.
All of this penny stock activity has not gone unnoticed by federal regulators. As the Financial Times reported, the Securities and Exchange Commission last month suspended trading in SpectraScience after the “seemingly defunct” Minnesota-based healthcare company attracted attention from a large number of penny-stock investors.
According to the SEC, a coordinated attempt by social media might have “artificially influenced” the share price of SpectraScience — a company that The Financial Times said doesn’t have a working phone line or website and hasn’t filed quarterly financial results since 2017.
More from GOBankingRates